2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 2, 2003, Pages 185-192

  Pan, Kevin ^a   Scott, Malcolm K ^a   Lee, Daniel H S ^a,b   Fitzpatrick, Louis J ^a   Crooke, Jeffery J ^a   Rivero, Ralph A ^a,c   Rosenthal, Daniel I ^a   Vaidya, Anil H ^a   Zhao, Boyu ^a   Reitz, Allen B ^a  

^a Drug Discovery   (United States)

^b BIOGEN   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYLPHENYL) 3 PHENYL 5 (4 METHOXYPHENYLAMINO)[1,2,4]THIADIAZOLINE; 2 (2 METHYLPHENYL) 3 PHENYL 5 [N METHYL N (4 METHOXYPHENYL)AMINO][1,2,4]THIADIAZOLIUM TRIFLATE; 2 (4 METHYLPHENYL) 3 PHENYL 5 (4 METHOXYPHENYLAMINO)[1,2,4]THIADIAZOL 2 IUM BROMIDE; MELANOCORTIN MC4 RECEPTOR AGONIST; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ALPHA INTERMEDIN; CORTICOTROPIN RECEPTOR; DRUG DERIVATIVE; MELANOCORTIN 4 RECEPTOR; MSH, 4 NLE 7 PHE ALPHA; MSH, 4-NLE-7-PHE-ALPHA-; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; FEEDING BEHAVIOR; FOOD INTAKE; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL CULTURE; DIET RESTRICTION; DISEASE MODEL; DRUG POTENTIATION; INFUSION; LONG EVANS RAT; MELANOMA; METABOLISM; PHYSIOLOGY; SYNTHESIS;

ALPHA-MSH; ANIMALS; DISEASE MODELS, ANIMAL; FASTING; FEEDING BEHAVIOR; HUMANS; INFUSIONS, PARENTERAL; INHIBITORY CONCENTRATION 50; IODINE RADIOISOTOPES; MALE; MELANOMA; RATS; RATS, LONG-EVANS; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, CORTICOTROPIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES; TUMOR CELLS, CULTURED;

EID: 0037449353     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00428-5     Document Type: Article

References (33)

1. (a) Haskell-Luevano C., Hadley M.E. Drug News Perspectives. 12:1999;197 (b) Wikberg J.E.S., Muceniece R., Mandrika I., Prusis P., Lindblom J., Post C., Skottner A. Pharmacol. Res. 42:2000;393 (c) Wikberg J.E. Exp. Opin. Ther. Patents. 11:2001;61.
2. Chen, W. In The Melanocortin Receptors, Cone, E. D., Ed.; Human Press: Totowa, NJ, 2000; p 449.
3. Abdel-Malek Z.A., Scott M.C., Furumura M., Lamoureux M.L., Ollmann M., Barsh G.S., Hearing V.J. J. Cell. Sci. 114:2001;1019.
4. (a) Yang Y.-K., Thompson D.A., Dickinson C.J., Wilken J., Barsh G.S., Kent S.B.H., Gantz I. Endocrinology. 13:1999;148 (b) Ollmann M.M., Wilson B.D., Ying-Kui Y., Kerns J.A., Chen Y., Gantz I., Barsh G.S. Science. 278:1997;135.
5. (a) MacNeil D.J., Howard A.D., Guan X., Fong T.M., Nargund R.P., Bednarek M.A., Boulet M.T., Weinberg D.H., Strack A.M., Marsh D.J., Chen H.Y., Shen C.P., Chen A.S., Rosenblum C.I., MacNeil T., Tota M., MacIntyre E.D., van der Ploeg L.H.T. Eur. J. Pharmacol. 440:2002;141 (b) Adan R.A., Gispen W.H. Eur. J. Pharmacol. 405:2000;13.
6. (a) Alvaro J.D., Tatro J.B., Quillan J.M., Fogliano M., Eisenhard M., Lerner M.R., Nestler E.J., Duman R.S. Mol. Pharm. 50:1996;583 (b) Alvaro J.D., Tatro J.B., Duman R.S. Life Sci. 61:1997;1.
7. For a review of the function of the MC4 receptor on neurotrophic and neuroprotective actions, see Hol E.M., Gispen W.H., Baer P.R. Peptides. 16:1995;979.
8. Adan R.A.H., van der Kraan M., Doornbos R.P., Bar P.R., Burbach J.P.H., Gispen W.H. Mol. Brain Res. 36:1996;37.
9. (a) Poggioli R., Vergoni A.V., Bertolini A. Peptides. 7:1986;843 (b) Vergoni A.V., Poggioli R., Bertolini A. Neuropeptides. 7:1986;153.
10. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Nature. 385:1997;165.
11. Woychik, R. P. US Patent 6080550, 2000.
12. Kask A., Rago L., Mutulis F., Pahkla R., Wirkberg J.E.S., Schioth H.B. Biomed. Biophys. Res. Comm. 245:1998;90.
13. Huszar D., Lynch C., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R., Boston B., Cone R., Smith F., Campfield L.A., Burn P., Lee F. Cell. 88:1997;131.
14. Yeo G.S., Farooqi I.S., Aminian S., Halsall D.J., Stanhope R.G., O'Rahilly S. Nat. Genet. 20:1998;111.
15. Kordik C.P., Reitz A.B. J. Med. Chem. 42:1999;181.
16. Haskell-Leuvano C., Hendrata S., North C., Sawyer T.K., Hadley M.E., Hruby V.J., Dickinson C., Gantz I. J. Med. Chem. 40:1997;2133.
17. Bednarek M.A., MacNeil T., Kalyani R.N., Tang R., van der Ploeg L.H.T., Weinberg D.H. Biomed. Biophys. Res. Comm. 261:1999;209.
18. Schioth H.B., Muceniece R., Mutulis F., Bouifrouri A.A., Mutule I., Wikberg J.E.S. Neuropeptides. 33:1999;191.
19. (a) Dorr R.T., Lines R., Levine N., Brooks C., Xiang L., Hruby V.J., Hadley M.E. Life Sci. 58:1996;1777 (b) Wessells H., Fuciarelli K., Hansen J., Hruby V.J., Dorr R., Levine N. J. Urol. 160:1998;389.
20. Basu A., Gahman T.C., Girten B.E., Griffith M.C., Hecht C.C., Kiely J.S., Silvka S.R., Dines K.S. WO. 1999;9955679.
21. Nargund, R. P.; Sebhat, I. K.; Ye, Z.; Barakat, K.; Weinberg, D.; MacNeil, T. Book of Abstracts, Part 1, 222nd National Meeting of the American Chemical Society, Chicago, IL, 26-30 August 2001; American Chemical Society: Washington, DC, 2001; MEDI 151.
22. (a) Kihara Y., Kabashima S., Uno K., Okawara T., Yamasaki T., Furukawa M. Synthesis. 1990;1020 (b) Bohrisch J., Patzel M., Grubert L., Liebscher J. Phos. Sulfur Silicon. 84:1993;253 (c) Chetia J.P., Mazumder S.N., Mahahan M.P. Synthesis. 1985;83 (d) Goerdeler J., Lobach W. Chem. Ber. 112:1979;517.
23. Ogonor J.I. Tetrahedron. 37:1981;2909.
24. Singh B., Collins J.C. J. Chem. Soc., Chem. Commum. 1971;498.
25. Schwenker G., Kolb R. Tetrahedron. 25:1969;5437.
26. Compound 3a was completely reduced to 7a after mixing with 10 mL-equiv DTE in dichloromethane for 20 min.
27. Pan, K.; Reitz, A. Manuscript submitted for publication.
28. (a). It does not appear that the Bowes melanoma cell line expresses the MC-1 receptor: Lombardi T., Castellucci M. Virchows Archiv B. Cell Path. Mol. Path. 58:1990;181 (b) Schioeth H.B., Kuusinen A., Muceniece R., Szardenings M., Keinaenen K., Wikberg J.E.S. Biochem. Biophys. Res. Commun. 221:1996;807.
29. (a) Bowden C.R., White K.D., Tutwiler G.F. J. Obesity Weight Regul. 4:1985;5 (b) Kordik C.P., Luo C., Zanoni B.C., Lovenberg T.W., Wilson S.J., Vaidya A.H., Crooke J.J., Rosenthal D.I., Reitz A.B. Bioorg. Med. Chem. Lett. 11:2001;2287.
30. Compound 3a was tested in two independent GTP-γS binding assays (n=4), and α-MSH was used as a positive control. Compound 3a showed increased binding (37.5±6.9% at 10 nM, 76.5±11.2% at 100 nM, and 106.5±11.8% at 1000 nM), comparable to the effect seen with α-MSH (33.5±3.1% at 10 nM, 84.0±11.1% at 100 nM, and 211.3±12.5% at 1000 nM).
31. Pandey A.K., Singh R., Verma V.K. J. India Chem Soc. 64:1987;675.
32. Haskell-Luevano C., Sawyer T.K., Trumpp-Kallmeyer S., Bikker J.A., Humblet C., Gantz I., Hruby V.J. Drug Des. Disc. 14:1996;197.
33. The pKa value for 3a was measured by pION, Inc., 5 Constitution Way, Woburn, MA 01801.